FDA Considers Easing Peptide Restrictions as RFK Jr. Voices Support

The FDA announced on April 15, 2026 that it will convene a panel of outside advisers in July 2026 to review whether seven peptides, including BPC-157, should be added to a list of substances that compounding pharmacies can safely produce. Health Secretary Robert F. Kennedy Jr., who has publicly discussed using peptides for his own injuries and previewed the announcement on Joe Rogan's podcast, has repeatedly pledged to loosen peptide regulations despite the FDA's 2023 restrictions citing safety risks including cancer and organ damage. The review comes after the Biden administration added nearly 20 peptides to the restricted substances list and FDA advisers voted overwhelmingly that peptides did not meet safety criteria for compounding, though many of those advisers no longer work at the agency. Critics including former FDA official Dr. Peter Lurie warn that allowing untested peptides threatens the FDA's drug approval system, while the compounding industry argues restrictions have created dangerous illicit markets for imported chemicals from China.

FDA's Shift Toward Easing Peptide Restrictions

• ▪The Food and Drug Administration will hold a meeting in summer 2026 to consider easing restrictions on more than a half dozen peptide injections.
• ▪Under President Joe Biden, the FDA added nearly 20 peptides to the federal list of substances that should not be produced by compounding pharmacies.
• ▪The FDA's pharmacy panel currently has a number of vacancies, which Kennedy could fill before the July 2026 meeting.
• ▪When the FDA added injectable peptides to its list of restricted substances in 2023, the agency cited safety risks including cancer and liver, kidney and heart problems.
• ▪The FDA announced on April 15, 2026 that it will ask a panel of outside advisers to review seven peptides at a meeting in July 2026.
• ▪The peptides under FDA review include BPC-157, which is marketed to heal injuries and reduce inflammation.

RFK Jr.'s Advocacy and Personal Use of Peptides

• ▪Gary Brecka, a self-described longevity expert who sells various peptide formulas through his website, is a major supporter of Robert F. Kennedy Jr.'s Make America Healthy Again movement.
• ▪Robert F. Kennedy Jr. previewed the FDA's April 15, 2026 announcement in an interview with podcast host Joe Rogan.
• ▪Health Secretary Robert F. Kennedy Jr. has made repeated pledges to loosen regulations on peptides.
• ▪Republican Senator Tommy Tuberville of Alabama sent letters to Robert F. Kennedy Jr. in 2025 asking him to lift limits on peptide production.
• ▪Robert F. Kennedy Jr. told Joe Rogan that he is a big fan of peptides and has used them with good effect on a couple of injuries.

Safety Concerns and Lack of Clinical Evidence

• ▪Several peptides, such as BPC-157 and TB-500, are banned by international sports authorities as doping substances.

The Unregulated Peptide Market and Industry Pressures

• ▪GLP-1 medications have achieved blockbuster success and are FDA-approved for treating obesity and diabetes.
• ▪The FDA's 2023 restrictions on injectable peptides triggered pushback from wellness entrepreneurs, compounding pharmacies and their allies in Washington.

Perspective of Compounding pharmacy industry

• ▪The Alliance for Pharmacy Compounding views the July 2026 FDA meeting as the beginning of a lengthy regulatory process.

2 sources